Reselute recently announced that Duke Capital Partners has led a seed investment in the company, supporting the continued development of its innovative orthopedic infection technology. The funding reflects growing confidence in Reselute’s mission to improve treatment options for complex bone infections.
Reselute was co-founded by Duke graduates Cambre Kelly and Jake Donovan alongside Duke engineering professor Ken Gall. The company is built on technology developed in Gall’s lab and licensed through Duke’s innovation ecosystem, with the goal of advancing new medical devices designed to stabilize fractures while delivering localized antibiotics directly to the surgical site.
With this investment, Reselute plans to accelerate research and development, expand its team, and continue progressing toward clinical solutions that help surgeons better manage orthopedic infections and improve outcomes for patients.
